Arecor Therapeutics plc

Equities

AREC

GB00BMWLM973

Biotechnology & Medical Research

Delayed London S.E. 06:19:30 2024-02-23 am EST 5-day change 1st Jan Change
140 GBX -3.45% Intraday chart for Arecor Therapeutics plc -9.68% -23.29%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Arecor Therapeutics hails Arestat as 2023 performance "strong" AN
Arecor pleased as investee Inhibrx sells therapy to Sanofi AN
Patent boosts for DG Innovate and Arecor Therapeutics AN
Arecor Therapeutics Gains European Patent for Insulin Product Formulations MT
Arecor expands speciality hospital collaboration with partner AN
Arecor Therapeutics Expands Formulation Study Collaboration with Pharmaceutical Partner MT
Arecor Therapeutics plc Expands Ongoing, Exclusive Formulation Study Collaboration with the Pharmaceutical Division of One of the World's Largest Chemicals Marketing and Pharmaceuticals Companies CI
Arecor inks co-development deal with global medical company AN
Arecor Therapeutics Signs Exclusive License Option Agreement for Oncology Product MT
Arecor Therapeutics plc Announces Co-Development and Exclusive Licence Option Agreement CI
Arecor inks Eli Lilly deal; RBG appoints McNair CFO AN
Arecor Therapeutics Signs Further Collaboration With Eli Lilly MT
Arecor Therapeutics plc Signs Further Collaboration Agreement with Lilly and Company CI
Arecor Therapeutics gets "milestone payment" from AT220 sale AN
Arecor Therapeutics to Receive Milestone Payment from Maiden Commercial Sale of Arestat Technology Product MT
Troy Income suspends buyback of shares AN
Arecor Therapeutics to Receive Milestone Payment from Inhibrx MT
Arecor Therapeutics ups subject numbers for insulin-focused trial AN
Arecor Therapeutics to Increase Patients in Phase 1 Trial of Insulin Candidate MT
Arecor Therapeutics plc Provides Update on Progress of Second Phase I Clinical Study of Ultra-rapid, Ultra-Concentrated Insulin Candidate AT278 CI
Oxford Technology 2 VCT asset value hurt by AIM share falls AN
Transcript : Arecor Therapeutics plc, H1 2023 Earnings Call, Sep 20, 2023
EARNINGS: Jersey O&G and World Chess losses widen, Arecor narrows AN
Transcript : Arecor Therapeutics plc, H1 2023 Earnings Call, Sep 14, 2023
Earnings Flash (AREC.L) ARECOR THERAPEUTICS Posts H1 Loss GBP-0.15 MT
Chart Arecor Therapeutics plc
More charts
Arecor Therapeutics plc is a globally focused biopharmaceutical company. The Company, through its formulation technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver formulations of their therapeutic products. Its clinical development programs include AT247-Ultra-Rapid Acting Insulin and AT278-Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. AT278 is a concentrated formulation of rapid acting insulin that is designed to accelerate the absorption of insulin post injection, even when delivered at a high concentration, and hence via a lower injection volume. It also has Tetris Pharma portfolio.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.45 GBP
Average target price
4.71 GBP
Spread / Average Target
+224.83%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Arecor Therapeutics plc - London S.E.
  4. News Arecor Therapeutics plc
  5. Arecor Therapeutics to Increase Patients in Phase 1 Trial of Insulin Candidate
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer